Table 2 Medication use of the trial participants at 6Â months of follow-up categorized by racial group
|  | Overall N = 14,665 | White N = 11,113 | Asian N = 1444 | Other races N = 1238 | Black N = 870 |
|---|---|---|---|---|---|
Diabetes therapy (alone/in combination): | Â | Â | Â | Â | Â |
 Metformin | 72.7% | 73.0% | 70.8% | 74.6% | 70.3% |
 Sulfonylurea/other secretagogue | 34.9% | 34.5% | 40.0% | 31.4% | 37.6% |
 Alpha-glucosidase inhibitors | 1.8% | 1.0% | 9.7% | 0.7% | 0.2% |
 Thiazolidinedione | 3.6% | 3.4% | 4.8% | 3.0% | 4.4% |
 Incretin-based therapies | 14.0% | 14.8% | 16.1% | 8.9% | 8.3% |
 Insulin | 45.0% | 45.1% | 44.7% | 46.5% | 41.6% |
Cardiovascular medications: | Â | Â | Â | Â | Â |
 Statins | 68.6% | 69.9% | 69.9% | 60.7% | 61.4% |
 ACE inhibitors or angiotensin receptor blockers | 74.3% | 76.4% | 64.1% | 70.0% | 71.1% |
 Diuretics | 42.3% | 45.6% | 20.8% | 33.5% | 48.4% |
 Calcium channel blockers | 30.7% | 30.3% | 36.4% | 24.7% | 34.5% |
 Beta blockers | 53.2% | 56.1% | 45.6% | 43.9% | 42.2% |
 Aspirin | 61.2% | 61.6% | 57.2% | 65.0% | 58.0% |
 Other anti-platelet function antagonists | 3.3% | 2.9% | 5.6% | 3.2% | 4.4% |